LEQEMBI (LECANEMAB) – WHAT IT IS AND HOW IT IS USED
Leqembi (generic name lecanemab) is an FDA-approved treatment for early Alzheimer’s disease and mild cognitive impairment due to Alzheimer’s. It is not a cure. Its purpose is to slow the rate of cognitive decline by reducing beta-amyloid plaque in the brain.

TYPICAL TREATMENT REGIMEN
Leqembi is given as an intravenous infusion. The standard dosing schedule is one infusion every two weeks over approximately one hour. Treatment is ongoing and long-term. After about eighteen months, some patients may transition to less frequent IV dosing or weekly under-the-skin injections. This makes the regimen cyclic with repeated infusion visits.

DIAGNOSTIC AND SAFETY SCREENING
Before starting treatment, patients are evaluated to confirm the diagnosis and determine safety. This can include cognitive testing, amyloid confirmation (PET scan or spinal fluid biomarkers), and a baseline MRI. APOE genetic testing may be used to determine risk for treatment-related complications.

WHY MRI MONITORING IS REQUIRED
Leqembi can cause ARIA (Amyloid-Related Imaging Abnormalities), which are changes visible on MRI involving brain swelling or small brain hemorrhages. Many cases have no symptoms, which is why scheduled MRI scans are built into the treatment plan.
Standard MRI monitoring includes:
A baseline MRI before the first infusion
Follow-up MRIs before the third, fifth, seventh, and fourteenth infusions
Additional MRI between the second and third infusion due to early-phase safety risk
More MRIs may be ordered if symptoms such as headaches or neurological changes occur.

INFUSION-SITE EFFECTS
Because Leqembi is administered through a peripheral IV line, usually in the hand or forearm, infusion-site bruising, mild swelling, or tenderness are common and expected with repeated access.

OTHER FOLLOW-UP TESTING
Follow-up may include:
Laboratory tests
Cognitive assessments
Physical and neurological exams

KEY POINTS
Drug name: Leqembi (lecanemab)
Mechanism: targeted removal of beta-amyloid plaque
Goal: slow cognitive decline in early disease
Modality: intravenous infusion
Interval: every two weeks
Safety monitoring: multiple scheduled MRIs
Infusion-site bruising is common

Before you decide, I'm crazy!!!

STOP AND THINK. about your family and what that would mean for ALL 18-35-year-olds.

STOP AND THINK. Why has it never been brought back since Vietnam? That was my time to serve, 1965-1969.

STOP AND THINK. WHY DO THEY WANT AN ALL-VOLUNTEER military? It grants them the political edge to say... , BUT IT IS AN ALL-VOLUNTEER FORCE!

STOP AND THINK. Recent numbers suggest that historically, only 1% of the population has served in the military.

STOP AND THINK about how they are going to put boots on the ground across the entire "Western Hemisphere": Greenland, Canada, America, Mexico, Cuba, South America (all of it).

How do we know the real "Resolute Desk" was returned to the Oval Office? It wouldn't be unreasonable to assume that the real desk is somewhere, waiting to find its reserved space in the presidential library. After all, there was a bathroom full of TOP SECRET documents that were procured illegally ..... all right, stolen. And then the White House East Wing was torn down WITHOUT AUTHORIZATION.

Just asking who DOES THE "Resolute Desk" belong to?

Leqembi (lecanemab) is an FDA-approved IV treatment for early Alzheimer’s disease that modestly slows cognitive decline, but does not cure or reverse the disease.

Once treatment starts, doctors closely monitor patients through bi-weekly infusions, scheduled brain MRIs, and continuous symptom tracking, especially during the first 3 months when risks are highest.

MRI surveillance focuses on detecting ARIA—brain swelling or small bleeds—which can require pausing or stopping treatment.

Cognitive testing tracks the rate of decline, not improvement. Most critical safety signals come from caregiver observations between visits.

In practice, Leqembi is less about the infusion itself and more about ongoing imaging, vigilance, and risk management.

I would like to point out that Trump is secure in his belief that the SCOTUS' immunity decision will protect him from ever going to prison.

I can almost guarantee that he is going to "prison".

Let me explain, he may never spend a day behind bars.

But his demonstrated behavior, especially when the cameras are not on him, as shown in the picture above and additional photos of him sleeping or comatose in his chair. PROVES without a doubt that the doctors and experts are right.

He has dementia, and to date, there IS no cure, so it's only going to get worse.

So he is going into a prison with no escape. His own dementia mind. Where he won't even know his own family, and his stolen riches have no value. IT IS AN END-OF-LIFE SENTENCE.

Spending Limits: Inmates are subject to a maximum spending limit of about $360 per month for commissary purchases. This money is used for items not issued as part of basic care, such as food, hygiene products, and certain electronics. Phone calls, email, and other communication services are often separate expenses.